Writing on Stuff.co.nz* the University of Auckland’s Dr Francis Hunter outlines the situation PHARMAC and the Government face over the […]
Continue readingpharmac
Push for Keytruda funding – Expert reaction
Public pressure is growing for the Government to fund the melanoma drug Keytruda, listed as ‘low priority’ by drug funding […]
Continue readingTransparency needed in cancer drug markets – Expert reaction
Experts are calling for greater transparency and fairness in cancer drug pricing, in light of findings revealing discrepancies between Europe, […]
Continue readingPHARMAC not to fund melanoma drug – In the News
PHARMAC’s decision not to fund melanoma treatment pembrolizumab – marketed as Keytruda – has been widely covered in the media. Public […]
Continue readingNew melanoma drug in the headlines
A promising melanoma drug has doctors and patient groups calling for the medicine to be funded by PHARMAC in New […]
Continue readingTrade deals and healthcare – Prof John McMillan
On the university of Otago Bioethics Centre blog, centre Director Prof John McMillan writes about the leaked details of the […]
Continue readingUPDATED: Funding new medicines in NZ – Expert reaction
Funding new medicines in New Zealand can take over eight years and recommending a drug as high priority does not […]
Continue readingPHARMAC funds genetically-targeted Hep C drug
PHARMAC has announced it will fund a new hepatitis C drug targeted to patients who carry a particular gene variant, […]
Continue readingDrug funding key issue at conference
Academics, advocates, patients and politicians wrestled over the legal, ethical and scientific issues surrounding the funding of treatments for suffers […]
Continue readingResearch raises concern over sleeping pills
New research has found that several commonly prescribed sleeping pills are associated with a more than fourfold increased risk of […]
Continue reading